Decibel

Decibel Expands Global Footprint with Agreement to Supply Medical Cannabis to 4C LABS for Distribution in the United Kingdom

Retrieved on: 
Wednesday, August 30, 2023

Decibel to supply 4C LABS with Qwest branded, craft-quality Medical Cannabis for distribution to UK medical cannabis patients

Key Points: 
  • Decibel to supply 4C LABS with Qwest branded, craft-quality Medical Cannabis for distribution to UK medical cannabis patients
    "We are excited to partner with 4C LABS, a leading organization in the growing medical cannabis industry in the UK, that echoes Decibel's commitment to quality and patient care.
  • "Decibel's success with Qwest flower products in Canada and in Israel's medical market reinforces the demand for premium cannabis products and the reputation we have built to service that demand."
  • "4C LABS is building a patient focused best-in-class product line for the UK & Channel Islands, the Qwest craft flower line strengthens the top end of the 4C LABS product offerings.
  • Decibel's innovative craft quality Qwest flower products will fill an empty segment in the UK market and bring a world class BC Cannabis product to UK patients," said Greg Dobbin, CEO 4C LABS.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, AMED, RETA, SURF

Retrieved on: 
Tuesday, August 29, 2023

If you are a Decibel shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Decibel shareholder, click here to learn more about your rights and options .
  • If you are an Amedisys shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm

Retrieved on: 
Tuesday, August 29, 2023

Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.

Key Points: 
  • Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
  • Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq.
  • Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
  • Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRTV, DBTX, CPRI, AVID

Retrieved on: 
Wednesday, August 23, 2023

If you are a Veritiv shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Veritiv shareholder, click here to learn more about your rights and options .
  • If you are a Decibel shareholder, click here to learn more about your rights and options .
  • If you are an Avid shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Moore Kuehn Encourages DBTX, AVID, CPRI, and ARCE Investors to Contact Law Firm

Retrieved on: 
Tuesday, August 22, 2023

Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.

Key Points: 
  • Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
  • Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq.
  • Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
  • Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.

DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX

Retrieved on: 
Saturday, August 12, 2023

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Decibel Therapeutics, Inc. (NasdaqGS: DBTX) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Decibel Therapeutics, Inc. (NasdaqGS: DBTX) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, DBTX

Retrieved on: 
Friday, August 11, 2023

If you are a Computer Task shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Computer Task shareholder, click here to learn more about your rights and options .
  • If you are a Decibel shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Friday, August 11, 2023

BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • In May 2023, Decibel announced the initiation of CHORD, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients.
  • Second Quarter 2023 Financial Results:
    Cash Position: As of June 30, 2023, cash, cash equivalents and available-for-sale securities were $78.3 million, compared to $104.6 million as of December 31, 2022.
  • Research and Development Expenses: Research and development expenses were $12.8 million for the second quarter of 2023, compared to $11.2 million for the same period in 2022.
  • General and Administrative Expenses: General and administrative expenses were $6.2 million for the second quarter of 2023, compared to $5.9 million for the same period in 2022.

DBTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Decibel Therapeutics, Inc. Is Fair to Shareholders

Retrieved on: 
Wednesday, August 9, 2023

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Decibel Therapeutics, Inc. (NASDAQ: DBTX) to Regeneron Pharmaceuticals, Inc. is fair to Decibel shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Decibel Therapeutics, Inc. (NASDAQ: DBTX) to Regeneron Pharmaceuticals, Inc. is fair to Decibel shareholders.
  • Under the merger, Decibel shareholders will receive $4.00 per share in cash and a non-tradeable contingent value right entitling such holders to receive up to $3.50 per share in cash if certain clinical development and regulatory milestones are achieved.
  • On behalf of Decibel shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

DBTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Decibel Therapeutics to Regeneron Pharmaceuticals

Retrieved on: 
Wednesday, August 9, 2023

MONSEY, N.Y., Aug. 09, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the $4.00 per share in cash, plus a contingent value right (“CVR”) for up to $3.50 per share in cash, pursuant to which Decibel Therapeutics, Inc. (Nasdaq: DBTX) (“Decibel”) has agreed to be sold to Regeneron Pharmaceuticals, Inc. (“Regeneron”) via a tender offer.

Key Points: 
  • MONSEY, N.Y., Aug. 09, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the $4.00 per share in cash, plus a contingent value right (“CVR”) for up to $3.50 per share in cash, pursuant to which Decibel Therapeutics, Inc. (Nasdaq: DBTX) (“Decibel”) has agreed to be sold to Regeneron Pharmaceuticals, Inc. (“Regeneron”) via a tender offer.
  • If you remain a Decibel shareholder and question the fairness of the price, you may contact our firm at the following link to discuss your legal rights at no charge:
    Alternatively, you may contact us by phone at 866-833-6245, or via email at [email protected] .
  • Why is there an investigation?
  • “We are investigating whether the Decibel Board of Directors acted in the best interests of Decibel shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter.